Melanoma/Immunotherapy Bridge meetings opened today; American Society of Hematology event begins Saturday
- 3 faculty leaders will speak at Immunotherapy/Melanoma Bridge meetings
- 5 Roswell Park physicians will give invited talks as part of ASH 2020
- Topics include new treatment options, applications for next-gen sequencing
BUFFALO, N.Y. — Research and insights from the Roswell Park Comprehensive Cancer Center team will help to fuel three important research meetings in the week ahead as researchers in oncology, hematology and immunotherapy come together virtually for the Immunotherapy Bridge 2020 meeting, Melanoma Bridge 2020 meeting and 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
“We look forward to these meetings every year and take very seriously our obligation to share new study results and open up dialogue about the questions and opportunities they raise,” says Igor Puzanov, MD, MSCI, FACP, Senior Vice President for Clinical Investigation, Director of the Center for Early Phase Clinical Trials and Chief of Melanoma. “The clinical trials our team is leading today will help to drive improvements in outcomes and patient experience tomorrow.”
Bridge Meetings
Dr. Puzanov is one of the organizers of the Immunotherapy Bridge 2020 and Melanoma Bridge 2020 meetings, which begin today and continue through Saturday, December 5. Both a Co-President and member of the scientific boards for these companion meetings, he is co-chair and panelist for several sessions during these companion meetings, and will give a talk Saturday, Dec. 5, on oncolytic virus combinations incorporating checkpoint inhibitors, during the Emergent Strategies session.
Kunle Odunsi, MD, FRCOG, FACOG, Deputy Director, Chair of Gynecologic Oncology and Executive Director of the Center for Immunotherapy, will present on adaptive metabolic rewiring of the tumor microenvironment and IDO blockade in ovarian cancer during Immunotherapy Bridge 2020, and Pawel Kalinski, MD, PhD, Vice Chair for Translational Research, will discuss targeting of dendritic cells to enhance PD1 blockade against cold tumors as part of Melanoma Bridge 2020.
ASH 2020
The leaders of the four branches of Roswell Park’s hematologic oncology program — transplant and cellular therapy, leukemia, lymphoma and myeloma — will play active roles in and around ASH 2020, which runs Dec. 5-8.
Philip McCarthy, MD, Director of the Transplant & Cellular Therapy Center, is co-chair and moderator of Scientific Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma, a Dec. 3 workshop organized by the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup. During the workshop, Jens Hillengass, MD, PhD, Chief of Myeloma, will moderate a session on next-generation sequencing and flow cytometry, and Maximilian Merz, MD, Assistant Professor of Oncology, will give a presentation on single-cell sequencing of multiple myeloma tumors.
Several Roswell Park faculty members will give virtual talks as part of the ASH 2020 Scientific Program. Presentation details:
Phase 3, Multicenter, Open-Label Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy
Abstract number: 27
Presenter: Eunice Wang, MD, Chief of Leukemia
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel combination therapies in treatment of newly diagnosed AML
Time: Saturday, Dec. 5, 8:15 a.m. PST/11:15 a.m. EST
Location: Channel 12 (Virtual Meeting)
Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Abstract number: 115
Presenter: Eunice Wang, MD, Chief of Leukemia
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel promising therapies for relapsed/refractory AML
Time: Saturday, Dec. 5, 11:30 a.m. PST/1:30 p.m. EST
Location: Channel 12 (Virtual Meeting)
Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma
Abstract number: 722
Presenter: Maximilian Merz, MD, Assistant Professor of Oncology, first author; Dr. Hillengass contributed to this work as senior author
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy II
Time: Monday, Dec. 7, 2:15 p.m. PST/5:15 p.m. EST
Location: Channel 11 (Virtual Meeting)
Hernandez-Ilizaliturri
A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results
Abstract number: 701
Presenter: Francisco Hernandez-Ilizaliturri, MD, Chief of Lymphoma
Session: 623. Mantle Cell and Indolent B-Cell Lymphoma - CAR-T and immunotherapy clinical studies
Time: Monday, Dec. 7, 1:45 p.m. PST/4:45 p.m. EST
Location: Channel 7 (Virtual Meeting)
During Saturday’s presentations, Dr. Hernandez-Ilizaliturri will also serve as a moderator on Session 623, Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma Clinical Trials. And on Monday, Dec. 7, Dr. Wang will give a talk in an ASH Education session during the meeting titled Management of Toxicities Associated with Targeted Therapies: When to Push Through and When to Stop. Roswell Park team members will also present several poster abstracts during the meeting.
Check the Roswell Park Newsroom for additional updates during the meetings, and follow the conference hash tags on Twitter: #Bridge20 and #ASH20.
###
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.
Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org